Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study on Etavopivat in Participants With and Without Liver Disease

Phase 1

Recruiting

Conditions: Liver Diseases

Interventions: Drug: Etavopivat

First Posted Date: 2024-03-28

Last Posted Date: 2024-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT06336018

Locations: 🇺🇸
Amer. Rrsch Corp-TX Liver Inst, San Antonio, Texas, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People

Phase 1

Recruiting

Conditions: Cardiometabolic Diseases
Healthy Volunteers

Interventions: Drug: NNC6022-0001
Drug: Placebo (NNC6022-0001)

First Posted Date: 2024-03-28

Last Posted Date: 2024-04-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT06336005

Locations: 🇳🇱
ICON - location Groningen, Groningen, Netherlands

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

Phase 2

Active, not recruiting

Conditions: Obesity

Interventions: Drug: NNC0519-0130
Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2024-03-22

Last Posted Date: 2024-08-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 355

Registration Number: NCT06326060

Locations: 🇺🇸
Velocity Clinical Res-Dallas, Dallas, Texas, United States
🇺🇸
UT Southwestern Medical Center - Lingvay, Dallas, Texas, United States
🇦🇺
Paratus Clinical, Herston, Queensland, Australia

and more 41 locations

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0519-0130
Drug: Placebo
Drug: Trizepatide

First Posted Date: 2024-03-22

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 288

Registration Number: NCT06326047

Locations: 🇺🇸
310 Clinical Research, Inglewood, California, United States
🇺🇸
Excel Clinical Network, Las Vegas, Nevada, United States
🇺🇸
Zenos Clinical research, Dallas, Texas, United States

and more 89 locations

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Phase 3

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Cagrilintide
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2024-03-21

Last Posted Date: 2024-12-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 180

Registration Number: NCT06323174

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Velocity Clinical Res-Dallas, Dallas, Texas, United States
🇸🇦
National Guard Hospital - Jeddah, Jeddah, Saudi Arabia

and more 46 locations

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Cagrilintide
Drug: Semaglutide

First Posted Date: 2024-03-21

Last Posted Date: 2024-12-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 270

Registration Number: NCT06323161

Locations: 🇺🇸
Bioclinical Research Alliance, Miami, Florida, United States
🇺🇸
Velocity Clinical Res-Dallas, Dallas, Texas, United States
🇺🇸
Palm Research Center Inc., Las Vegas, Nevada, United States

and more 46 locations

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

Completed

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)
Systemic Inflammation
Chronic Kidney Disease (CKD)

Interventions: Other: No treatment given

First Posted Date: 2024-03-21

Last Posted Date: 2024-07-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT06322641

Locations: 🇺🇸
KJT Group, Inc., Rochester, New York, United States

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Decitabine-THU

First Posted Date: 2024-03-04

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT06291285

Locations: 🇺🇸
ICON-Salt Lake City, Salt Lake City, Utah, United States
🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: Cagrilintide
Drug: Semaglutide
Drug: Atorvastatin
Drug: Warfarin

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT06289504

Locations: 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada

Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study

Completed

Conditions: Obesity

Interventions: Other: No treatment given

First Posted Date: 2024-03-01

Last Posted Date: 2024-10-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1322

Registration Number: NCT06288399

Locations: 🇰🇼
Farwaniya Hospital, Farwaniya, Kuwait
🇰🇼
Al-Adan Hospital, Hadiya, Kuwait
🇰🇼
Al-Amiri Hospital, Kuwait City, Kuwait

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy